Payment overview · 2025
General Payments
$319.55
17 reported records · 12 companies
Healthcare provider profile · identity verified
Mark Dawson, M.D.
Allopathic & Osteopathic Physicians|Pediatrics · RAYNE, LA · NPI 1043210271
Verified facts
What the public records show
CMS Open Payments records show Mark Dawson, M.D. received $319.55 in general payments during 2025 across 17 reported records.
ABBVIE INC. accounted for 26.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Viberzi.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIBERZI as an associated drug or biological on 11354 records involving 5020 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Viberzi by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Ozempic by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $84.22 | 26.4% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $40.35 | 12.6% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $32.76 | 10.2% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $26.14 | 8.2% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $21.21 | 6.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.27 | 6.3% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $18.97 | 5.9% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.08 | 5.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.40 | 5.1% | 1 | 2025 |
| Bioventus LLC | Unresolved — no canonical attribution shown | $16.19 | 5.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.24 | 4.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $9.72 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $319.55 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $67.59 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $40.35 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $35.69 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $32.76 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $26.14 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $21.21 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.27 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $18.08 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $16.63 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $16.40 | 1 | 2025 |
Source payment records
|
|||||
| DUROLANE Normalized: durolane |
Device | Bioventus LLC | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.24 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $9.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 116 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VIBERZI viberzi |
2025 | Viberzi | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
82 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIBERZI open payments reported associated product |
CMS Open Payments — General Payments 11354 supporting records · 5020 recipient NPIs · example record 1201352948 |
Viberzi · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
116 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
106 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 681 | 110 |
| Amlodipine Besylate | Amlodipine Besylate | 611 | 109 |
| Levothyroxine Sodium | Levothyroxine Sodium | 585 | 74 |
| Lisinopril | Lisinopril | 457 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 447 | 86 |
| Furosemide | Furosemide | 433 | 76 |
| Metformin Hcl | Metformin Hcl | 401 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 389 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 314 | 67 |
| Simvastatin | Simvastatin | 306 | 52 |
| Omeprazole | Omeprazole | 291 | 47 |
| Gabapentin | Gabapentin | 281 | 51 |
| Risperidone | Risperidone | 254 | 25 |
| Trazodone Hcl | Trazodone Hcl | 233 | 38 |
| Alprazolam | Alprazolam | 224 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 215 | 55 |
| Losartan Potassium | Losartan Potassium | 208 | 35 |
| Lactulose | Lactulose | 207 | 29 |
| Meloxicam | Meloxicam | 206 | 40 |
| Quetiapine Fumarate | Quetiapine Fumarate | 205 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 194 | 60 |
| Carvedilol | Carvedilol | 193 | 41 |
| Metformin Hcl Er | Metformin Hcl | 175 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 174 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 171 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 167 | 32 |
| Levetiracetam | Levetiracetam | 163 | 25 |
| Potassium Chloride | Potassium Chloride | 163 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 159 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 155 | 24 |
| Glipizide | Glipizide | 155 | 28 |
| Eliquis | Apixaban | 146 | 22 |
| Montelukast Sodium | Montelukast Sodium | 145 | 26 |
| Divalproex Sodium | Divalproex Sodium | 135 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 134 | 19 |
| Sertraline Hcl | Sertraline Hcl | 134 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 132 | 27 |
| Olanzapine | Olanzapine | 131 | 16 |
| Mirtazapine | Mirtazapine | 128 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 125 | 20 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 121 | 14 |
| Jardiance | Empagliflozin | 116 | 17 |
| Tramadol Hcl | Tramadol Hcl | 116 | 35 |
| Ezetimibe | Ezetimibe | 111 | 26 |
| Famotidine | Famotidine | 108 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 106 | 20 |
| Trulicity | Dulaglutide | 106 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 105 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 99 | 23 |
| Mupirocin | Mupirocin | 98 | 41 |
| Oxcarbazepine | Oxcarbazepine | 97 | 16 |
| Finasteride | Finasteride | 96 | 17 |
| Benazepril Hcl | Benazepril Hcl | 95 | 15 |
| Glipizide Er | Glipizide | 95 | 15 |
| Januvia | Sitagliptin Phosphate | 95 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 92 | 19 |
| Allopurinol | Allopurinol | 90 | 18 |
| Cephalexin | Cephalexin | 89 | 70 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 87 | 13 |
| Clonidine Hcl | Clonidine Hcl | 84 | 16 |
| Alendronate Sodium | Alendronate Sodium | 82 | 11 |
| Buspirone Hcl | Buspirone Hcl | 82 | 19 |
| Linzess | Linaclotide | 82 | 13 |
| Benztropine Mesylate | Benztropine Mesylate | 81 | suppressed |
| Ketoconazole | Ketoconazole | 80 | 20 |
| Lorazepam | Lorazepam | 80 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 77 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 77 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 77 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 77 | 11 |
| Phenobarbital | Phenobarbital | 76 | suppressed |
| Xarelto | Rivaroxaban | 72 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 71 | 26 |
| Prednisone | Prednisone | 70 | 54 |
| Divalproex Sodium Er | Divalproex Sodium | 64 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 61 | 18 |
| Glimepiride | Glimepiride | 58 | 11 |
| Latanoprost | Latanoprost | 58 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 57 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 57 | 14 |
| Fenofibrate | Fenofibrate | 56 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 54 | 14 |
| Lovastatin | Lovastatin | 54 | suppressed |
| Memantine Hcl | Memantine Hcl | 48 | suppressed |
| Timolol Maleate | Timolol Maleate | 47 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 47 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 45 | suppressed |
| Phenytoin | Phenytoin | 44 | suppressed |
| Pregabalin | Pregabalin | 44 | suppressed |
| Estradiol | Estradiol | 43 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 43 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 43 | suppressed |
| Clonazepam | Clonazepam | 42 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 42 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 29 |
| Lamotrigine | Lamotrigine | 40 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 39 | suppressed |
| Spironolactone | Spironolactone | 39 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 38 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 38 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | suppressed |
| Atenolol | Atenolol | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 35 | suppressed |
| Carbamazepine | Carbamazepine | 34 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 34 | suppressed |
| Naproxen | Naproxen | 34 | suppressed |
| Aripiprazole | Aripiprazole | 33 | suppressed |
| Celecoxib | Celecoxib | 33 | suppressed |
| Valsartan | Valsartan | 33 | suppressed |
| Myrbetriq | Mirabegron | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Ozempic | Semaglutide | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Metronidazole | Metronidazole | 29 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 23 |
| Doxepin Hcl | Doxepin Hcl | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 27 | suppressed |
| Ofloxacin | Ofloxacin | 27 | 16 |
| Sucralfate | Sucralfate | 27 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 26 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 25 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Digoxin | Digoxin | 25 | suppressed |
| Erythromycin | Erythromycin Base | 25 | suppressed |
| Sodium Fluoride | Fluoride (Sodium) | 25 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 24 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 24 | suppressed |
| Methimazole | Methimazole | 24 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 24 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 23 | suppressed |
| Thioridazine Hcl | Thioridazine Hcl | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Sotalol | Sotalol Hcl | 22 | suppressed |
| Ursodiol | Ursodiol | 22 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 18 |
| Cyclosporine | Cyclosporine | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 19 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 19 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Fluvoxamine Maleate Er | Fluvoxamine Maleate | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Lybalvi | Olanzapine/Samidorphan Malate | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 16 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 16 | 14 |
| Lithium Carbonate Er | Lithium Carbonate | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Paliperidone Er | Paliperidone | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Humalog | Insulin Lispro | 15 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Blisovi Fe | Norethindrone-E.Estradiol-Iron | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Loxapine | Loxapine Succinate | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Acetazolamide | Acetazolamide | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 13 | suppressed |
| Lumigan | Bimatoprost | 13 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 13 | suppressed |
| Valproic Acid | Valproic Acid | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Enulose | Lactulose | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Fyavolv | Norethindrone Ac/Eth Estradiol | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Travoprost | Travoprost | 11 | suppressed |
| Viberzi | Eluxadoline | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $319.55 · 17 records | ABBVIE INC. | Azstarys, Cologuard Collection Kit, DUROLANE, JARDIANCE, Jornay PM, NEXLETOL, Ozempic, QULIPTA, TZIELD, UBRELVY, VIBERZI, VOQUEZNA, XIFAXAN, ZORYVE | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error